CS
VIVO

Credit Suisse’s Meridian Bioscience Inc VIVO Stock Holding History

Credit Suisse’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-134,566
Closed -$4.47M – 3951
2022
Q4 		$4.47M Sell
134,566
-5,068
-4% -$163K ﹤0.01% 1379
2022
Q3 		$4.4M Buy
139,634
+105,441
+308% +$3.41M ﹤0.01% 1330
2022
Q2 		$1.04M Sell
34,193
-4,278
-11% -$116K ﹤0.01% 2350
2022
Q1 		$998K Buy
38,471
+4,314
+13% +$103K ﹤0.01% 2550
2021
Q4 		$697K Buy
34,157
+2,285
+7% +$43.8K ﹤0.01% 3590
2021
Q3 		$614K Sell
31,872
-3,289
-9% -$65.6K ﹤0.01% 3675
2021
Q2 		$780K Sell
35,161
-3,821
-10% -$81K ﹤0.01% 3564
2021
Q1 		$1.02M Sell
38,982
-8,544
-18% -$203K ﹤0.01% 3310
2020
Q4 		$888K Buy
47,526
+21,644
+84% +$404K ﹤0.01% 3413
2020
Q3 		$439K Sell
25,882
-2,863
-10% -$55.6K ﹤0.01% 3457
2020
Q2 		$669K Buy
28,745
+2,801
+11% +$40.6K ﹤0.01% 3150
2020
Q1 		$218K Sell
25,944
-19,417
-43% -$163K ﹤0.01% 3606
2019
Q4 		$444K Buy
45,361
+14,612
+48% +$137K ﹤0.01% 3636
2019
Q3 		$292K Buy
30,749
+2,990
+11% +$31.5K ﹤0.01% 3711
2019
Q2 		$329K Sell
27,759
-32,946
-54% -$397K ﹤0.01% 3642
2019
Q1 		$1.07M Buy
60,705
+7,621
+14% +$127K ﹤0.01% 2832
2018
Q4 		$921K Buy
53,084
+12,247
+30% +$209K ﹤0.01% 2843
2018
Q3 		$608K Sell
40,837
-101,606
-71% -$1.58M ﹤0.01% 3183
2018
Q2 		$2.27M Sell
142,443
-7,528
-5% -$112K ﹤0.01% 2350
2018
Q1 		$2.13M Buy
149,971
+1,528
+1% +$22.6K ﹤0.01% 2362
2017
Q4 		$2.08M Sell
148,443
-15,633
-10% -$229K ﹤0.01% 2404
2017
Q3 		$2.35M Buy
164,076
+29,405
+22% +$420K ﹤0.01% 2408
2017
Q2 		$2.12M Sell
134,671
-19,729
-13% -$284K ﹤0.01% 2191
2017
Q1 		$2.13M Buy
154,400
+77,859
+102% +$1.09M ﹤0.01% 2304
2016
Q4 		$1.35M Buy
76,541
+20,772
+37% +$365K ﹤0.01% 2775
2016
Q3 		$1.07M Sell
55,769
-5,886
-10% -$115K ﹤0.01% 2899
2016
Q2 		$1.2M Buy
61,655
+25,250
+69% +$495K ﹤0.01% 2773
2016
Q1 		$749K Sell
36,405
-10,425
-22% -$205K ﹤0.01% 2944
2015
Q4 		$961K Sell
46,830
-7,823
-14% -$150K ﹤0.01% 2849
2015
Q3 		$934K Buy
54,653
+7,881
+17% +$144K ﹤0.01% 2882
2015
Q2 		$872K Sell
46,772
-5,561
-11% -$103K ﹤0.01% 3303
2015
Q1 		$999K Sell
52,333
-6,332
-11% -$117K ﹤0.01% 2976
2014
Q4 		$965K Sell
58,665
-1,719
-3% -$29.5K ﹤0.01% 3161
2014
Q3 		$1.07M Buy
60,384
+19,764
+49% +$388K ﹤0.01% 2994
2014
Q2 		$840K Sell
40,620
-12,635
-24% -$260K ﹤0.01% 3439
2014
Q1 		$1.16M Sell
53,255
-67,444
-56% -$1.55M ﹤0.01% 2990
2013
Q4 		$3.2M Buy
120,699
+30,405
+34% +$747K ﹤0.01% 2228
2013
Q3 		$2.13M Sell
90,294
-20,808
-19% -$486K ﹤0.01% 2341
2013
Q2 		$2.39M Buy
+111,102
New +$2.4M ﹤0.01% 2137

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's VIVO Position: Q1 2023 in Review

Credit Suisse sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 134,566 shares — an estimated $4.47M sold.

Credit Suisse first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $4.47M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Credit Suisse reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 134,566 Meridian Bioscience Inc shares in Q1 2023, an estimated $4.47M.
  • Credit Suisse first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Credit Suisse's Meridian Bioscience Inc position peaked at $4.47M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.